{"success":true,"data":{"pressRelease":{"id":"108568","rtpr_id":"nGNXc9rXYF","ticker":"OKUR","exchange":"NASDAQ","all_tickers":["OKUR"],"title":"OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights                                               ","author":"Globe Newswire","published_at":"2026-08-04T20:05:03.146Z","article_body":"-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant\nselective candidates OKI-345 in breast cancer and OKI-355 in vascular\nanomalies, with IND submissions planned for 1H 2027\n\n-- Hosted a Key Opinion Leader event highlighting the evolving PI3Kα\ntreatment landscape and the scientific rationale supporting OnKure's\nnext-generation PI3Kα pan-mutant inhibitor programs\n\n-- Participated as an exhibitor and sponsor at the ISSVA World Congress 2026\nin Philadelphia, supporting engagement with leading vascular anomalies\nclinicians and researchers\n\n-- $176 million of cash, cash equivalents and marketable securities expected\nto fund operations into 2029\n\nBOULDER, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc.\n(Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on\ndeveloping novel precision medicines, today reported financial results for the\nsecond quarter ended June 30, 2026, and provided recent business highlights.\n\n“Following our strategic transformation earlier this year, we continue to\nadvance our next-generation PI3Kα pan-mutant selective inhibitor pipeline,\nwhich we believe represents the most compelling opportunity to deliver\ndifferentiated therapies across PI3Kα-driven diseases,” said Nicholas\nSaccomano, Ph.D., President and Chief Executive Officer of OnKure. “Both\nOKI-355 and OKI-345 continue to advance through IND-enabling activities and\nremain on track for planned IND submissions in the first half of 2027. We\nbelieve the combination of our chemistry platform and deep understanding of\nPI3Kα biology positions us to develop differentiated therapies with the\npotential to meaningfully improve outcomes for patients. Our recent Key\nOpinion Leader event reinforced the scientific rationale underpinning our\nstrategy and highlighted the significant opportunity for next-generation\nPI3Kα pan-mutant selective inhibitors to overcome the limitations of current\ntherapies across multiple disease settings.”\n\nVascular Anomalies\n\nOnKure continues to advance OKI-355, a next-generation PI3Kα\npan-mutant-selective inhibitor candidate announced in March 2026 to lead its\ndevelopment pipeline in vascular anomalies. OKI-355 has been designed to\nselectively inhibit mutant PI3Kα while sparing wildtype PI3Kα, potentially\nenabling a wider therapeutic index and avoidance of class-limiting toxicities.\nHigh and sustained target coverage across all hotspot PI3Kα mutations can\nsupport the potential for deep and durable responses in vascular anomalies.\nOnKure plans to submit an Investigational New Drug (IND) application to the\nU.S. Food and Drug Administration (FDA) for OKI-355 in the first half of 2027.\n\nAdditionally, earlier this year, OnKure initiated a discovery research program\nto expand its vascular anomalies pipeline beyond targeting PI3Kα.\n\nBreast Cancer\n\nIn breast cancer, OnKure continues to advance OKI-345, a next-generation\nPI3Kα pan-mutant-selective inhibitor candidate selected in March 2026.\nOKI-345 has been designed to selectively inhibit mutant PI3Kα while sparing\nwildtype PI3Kα, potentially enabling a wider therapeutic index and avoidance\nof class-limiting toxicities. High and sustained target coverage across all\nhotspot PI3Kα mutations can support the potential for deep and durable\nresponses in breast cancer, both as monotherapy and in combination. OnKure\nplans to submit an IND application to the FDA for OKI-345 in the first half of\n2027.\n\nScientific Engagement\n\nOnKure recently hosted a virtual Key Opinion Leader event titled \"Selectivity\nMatters and Pan-Mutant Allosteric Inhibition Delivers\n(https://www.globenewswire.com/Tracker?data=7WXAE3bqLjlEV5FgU2JrPB_1T4FTKxLSrfojGZq6NxK3ig8KbaS7YcYaVR94eoVF3dNmmZTvSobmkdmN8MltACeHrmny3jM7FmOFYb13Z24yUaCz9JaP4TIgFugDqMNyLsykrt06WhkiTMKQ7M4PepU-ZNv_DN0fkzJ3HY0Pj1oSOhe2EFcEtsoZc1Xmw7rRq-LfQ5HuWVgffw8t9-1sJfR7MoqqoeO2TZ4pNHg_C_1cSmmVzRD_HnKDOlV3PYW0P__EKmbe5aHi-jwgOn9Z8FJpPOJo87z9P4a-TAGdJ3MNNQzWMlS5X4F-QKbtnF7I),\"\nfeaturing Benjamin F. Cravatt, Ph.D., of Scripps Research, and Robert Abraham,\nPh.D., Chief Scientific Officer of Engine Biosciences. The discussion explored\nthe scientific rationale supporting next-generation PI3Kα pan-mutant\nselective inhibitors, including the importance of PI3Kα selectivity, the\npotential to overcome limitations of current therapies, and the Company's\nstructure-based drug design approach.\n\nOnKure also participated as an exhibitor and sponsor at the International\nSociety for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in\nPhiladelphia, held in May.\n\nFinancial Results\n\nCash position: As of June 30, 2026, the Company reported cash, cash\nequivalents, and marketable securities of $176.4 million, which is expected to\nprovide cash runway into 2029.\n\nResearch and development (R&D) expenses: R&D expenses were $12.6 million for\nboth the second quarter of 2026 and the second quarter of 2025. During the\nsecond quarter of 2026, an increase in clinical trial and outsourced\nmanufacturing expenses was offset by a decrease in outsourced preclinical R&D\nexpenses.\n\nGeneral and Administrative (G&A) expenses: G&A expenses were $4.3 million for\nthe second quarter of 2026, compared to $3.7 million for the second quarter of\n2025. The increase of $0.6 million was primarily driven by increases in\npersonnel-related and consulting costs.\n\nNet loss and net loss per share were $15.3 million, or $0.31 per share, for\nthe second quarter of 2026, compared to $15.4 million, or $1.14 per share, for\nthe second quarter of 2025.\n\nAbout OnKure Therapeutics\n\nOnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical\ncompany focused on the discovery and development of best-in-class precision\nmedicines that target biologically validated drivers of vascular anomalies and\ncancers that are underserved by available therapies. Using a structure and\ncomputational chemistry-driven drug design platform, OnKure is committed to\nimproving clinical outcomes for patients by building a pipeline of small\nmolecule drugs designed to selectively target specific mutations thought to be\nkey drivers of vascular anomalies and cancer. OnKure aims to become a leader\nin targeting PI3Kα and has multiple programs designed to enable best-in-class\ntargeting of this important molecular target.\n\nFor more information about OnKure, visit us at www.onkure.com and follow us on\nLinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that involve\nsubstantial risks and uncertainties. All statements other than statements of\nhistorical facts contained in this press release are forward-looking\nstatements. Such forward-looking statements include, among other things,\nstatements regarding the potential of, and expectations regarding, OnKure’s\nproduct candidates and programs, including OKI-355 and OKI-345; OnKure’s\nability to discover, develop and advance additional programs; expected\nmilestones and the timing of such milestones, including the submission of IND\napplications for OKI-355 and OKI-345; OnKure’s expected cash runway; and\nstatements by OnKure’s President and Chief Executive Officer. In some cases,\nyou can identify forward-looking statements by terminology such as\n“believe,” “expect,” “estimate,” “intend,” “may,”\n“plan,” “potentially,” “will” or the negative of these terms or\nother similar expressions.\n\nThese forward-looking statements are based largely on OnKure’s current\nexpectations and projections about future events and trends that OnKure\nbelieves may affect its financial condition, results of operations, business\nstrategy and financial needs. These forward-looking statements are subject to\na number of risks, uncertainties and assumptions, including, among other\nthings: OnKure’s limited operating history; the significant net losses\nincurred since inception; the ability to raise additional capital to finance\noperations; the risk that actual uses of cash and cash equivalents differ from\nthe assumptions underlying OnKure’s expected cash runway; the ability to\nadvance product candidates through preclinical and clinical development; the\nability to obtain regulatory approval for, and ultimately commercialize,\nOnKure’s product candidates; the outcome of preclinical testing and early\nclinical trials for OnKure’s product candidates, including the ability of\nthose trials to satisfy relevant governmental or regulatory requirements and\nthe potential that the outcome of preclinical testing and early clinical\ntrials may not be predictive of the success of later clinical trials;\nOnKure’s limited resources; the risk of adverse events, toxicities or other\nundesirable side effects; potential delays or difficulties in the enrollment\nor maintenance of patients in clinical trials; the decision to develop or seek\nstrategic collaborations to develop OnKure’s current or future product\ncandidates in combination with other therapies and the cost of combination\ntherapies; OnKure’s limited experience in designing clinical trials and lack\nof experience in conducting clinical trials; the substantial competition\nOnKure faces in discovering, developing, or commercializing products;\nOnKure’s ability to protect its intellectual property and proprietary\ntechnologies; developments relating to OnKure’s competitors and its\nindustry, including competing product candidates and therapies; reliance on\nthird parties, contract manufacturers, and contract research organizations;\nlegislative, regulatory, political and economic developments and general\nmarket conditions; and those risks described in the section entitled “Risk\nFactors” in documents that OnKure files from time to time with the SEC,\nincluding its Annual Report on Form 10-K filed with the SEC on March 12, 2026,\nits Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed\nwith the SEC on August 4, 2026, and any subsequent filings with the SEC. These\nrisks are not exhaustive. New risk factors emerge from time to time, and it is\nnot possible for OnKure’s management to predict all risk factors, nor can\nOnKure assess the impact of all factors on OnKure’s business or the extent\nto which any factor, or combination of factors, may cause actual results to\ndiffer materially from those contained in, or implied by, any forward-looking\nstatements. You should not rely upon forward-looking statements as predictions\nof future events. Although OnKure believes that the expectations reflected in\nthe forward-looking statements are reasonable, OnKure cannot guarantee future\nresults, levels of activity, performance or achievements. Except as required\nby law, OnKure undertakes no obligation to update publicly any forward-looking\nstatements for any reason after the date of this press release.\n\nContact:\n\nDan Ferry\nLifeSci Advisors\ndaniel@lifesciadvisors.com\n\n\n\n ONKURE THERAPEUTICS, INC.                                                                                                         \n Condensed Consolidated Balance Sheets                                                                                             \n (In thousands, unaudited)                                                                                                         \n                                                                                                                                   \n                                                                           June 30, 2026                   December 31, 2025       \n                                                                                                                                   \n Assets                                                                                                                            \n Current assets:                                                                                                                   \n Cash, cash equivalents and marketable securities                          $        176,386                $          59,050       \n Prepaid expenses and other current assets                                          1,291                             1,789        \n Total current assets                                                               177,677                           60,839       \n Property and equipment, net                                                        435                               618          \n Operating lease, right-of-use asset                                                840                               387          \n Other assets                                                                       401                               273          \n Total assets                                                              $        179,353                $          62,117       \n Liabilities and Stockholders’ Equity                                                                                              \n Current liabilities:                                                                                                              \n Accounts payable, accrued expenses, and other current liabilities         $        6,307                  $          5,372        \n Operating lease liabilities, current portion                                       336                               549          \n Total current liabilities                                                          6,643                             5,921        \n Long-term liabilities                                                              602                               12           \n Total liabilities                                                                  7,245                             5,933        \n Stockholders’ equity                                                               172,108                           56,184       \n Total liabilities and stockholders’ equity                                $        179,353                $          62,117       \n\n\n\n ONKURE THERAPEUTICS, INC.                                                                                                                                               \n Condensed Consolidated Statements of Operations                                                                                                                         \n (In thousands, except share and per share data, unaudited)                                                                                                              \n                                                                                                                                                                         \n                                                          Three Months Ended                                          Six Months Ended                                   \n                                                          June 30,                                                    June 30,                                           \n                                                          2026                          2025                          2026                          2025                 \n Operating expenses:                                                                                                                                                     \n Research and development                                 $     12,611                  $     12,613                  $     24,318                  $     25,625         \n General and administrative                                     4,288                         3,711                         8,196                         7,699          \n Total operating expenses                                       16,899                        16,324                        32,514                        33,324         \n Loss from operations                                           (16,899     )                 (16,324     )                 (32,514     )                 (33,324     )  \n Other income:                                                                                                                                                           \n Interest income                                                1,553                         934                           2,011                         2,009          \n Total other income                                             1,553                         934                           2,011                         2,009          \n Net loss                                                 $     (15,346     )           $     (15,390     )           $     (30,503     )           $     (31,315     )  \n                                                                                                                                                                         \n Net loss per share attributable to common stockholders:                                                                                                                 \n Basic and diluted                                        $     (0.31       )           $     (1.14       )           $     (0.96       )           $     (2.33       )  \n Weighted average shares outstanding:                                                                                                                                    \n Basic and diluted                                              49,869,177                    13,509,080                    31,871,862                    13,466,942     \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b01f7b95-9b60-4b2b-8515-fe0cae183fff)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXc9rXYF","title":"OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights                                               ","author":"Globe Newswire","ticker":"OKUR","created":"2026-08-04T20:05:03.146Z","tickers":["OKUR"],"exchange":"NASDAQ","article_body":"-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant\nselective candidates OKI-345 in breast cancer and OKI-355 in vascular\nanomalies, with IND submissions planned for 1H 2027\n\n-- Hosted a Key Opinion Leader event highlighting the evolving PI3Kα\ntreatment landscape and the scientific rationale supporting OnKure's\nnext-generation PI3Kα pan-mutant inhibitor programs\n\n-- Participated as an exhibitor and sponsor at the ISSVA World Congress 2026\nin Philadelphia, supporting engagement with leading vascular anomalies\nclinicians and researchers\n\n-- $176 million of cash, cash equivalents and marketable securities expected\nto fund operations into 2029\n\nBOULDER, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc.\n(Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on\ndeveloping novel precision medicines, today reported financial results for the\nsecond quarter ended June 30, 2026, and provided recent business highlights.\n\n“Following our strategic transformation earlier this year, we continue to\nadvance our next-generation PI3Kα pan-mutant selective inhibitor pipeline,\nwhich we believe represents the most compelling opportunity to deliver\ndifferentiated therapies across PI3Kα-driven diseases,” said Nicholas\nSaccomano, Ph.D., President and Chief Executive Officer of OnKure. “Both\nOKI-355 and OKI-345 continue to advance through IND-enabling activities and\nremain on track for planned IND submissions in the first half of 2027. We\nbelieve the combination of our chemistry platform and deep understanding of\nPI3Kα biology positions us to develop differentiated therapies with the\npotential to meaningfully improve outcomes for patients. Our recent Key\nOpinion Leader event reinforced the scientific rationale underpinning our\nstrategy and highlighted the significant opportunity for next-generation\nPI3Kα pan-mutant selective inhibitors to overcome the limitations of current\ntherapies across multiple disease settings.”\n\nVascular Anomalies\n\nOnKure continues to advance OKI-355, a next-generation PI3Kα\npan-mutant-selective inhibitor candidate announced in March 2026 to lead its\ndevelopment pipeline in vascular anomalies. OKI-355 has been designed to\nselectively inhibit mutant PI3Kα while sparing wildtype PI3Kα, potentially\nenabling a wider therapeutic index and avoidance of class-limiting toxicities.\nHigh and sustained target coverage across all hotspot PI3Kα mutations can\nsupport the potential for deep and durable responses in vascular anomalies.\nOnKure plans to submit an Investigational New Drug (IND) application to the\nU.S. Food and Drug Administration (FDA) for OKI-355 in the first half of 2027.\n\nAdditionally, earlier this year, OnKure initiated a discovery research program\nto expand its vascular anomalies pipeline beyond targeting PI3Kα.\n\nBreast Cancer\n\nIn breast cancer, OnKure continues to advance OKI-345, a next-generation\nPI3Kα pan-mutant-selective inhibitor candidate selected in March 2026.\nOKI-345 has been designed to selectively inhibit mutant PI3Kα while sparing\nwildtype PI3Kα, potentially enabling a wider therapeutic index and avoidance\nof class-limiting toxicities. High and sustained target coverage across all\nhotspot PI3Kα mutations can support the potential for deep and durable\nresponses in breast cancer, both as monotherapy and in combination. OnKure\nplans to submit an IND application to the FDA for OKI-345 in the first half of\n2027.\n\nScientific Engagement\n\nOnKure recently hosted a virtual Key Opinion Leader event titled \"Selectivity\nMatters and Pan-Mutant Allosteric Inhibition Delivers\n(https://www.globenewswire.com/Tracker?data=7WXAE3bqLjlEV5FgU2JrPB_1T4FTKxLSrfojGZq6NxK3ig8KbaS7YcYaVR94eoVF3dNmmZTvSobmkdmN8MltACeHrmny3jM7FmOFYb13Z24yUaCz9JaP4TIgFugDqMNyLsykrt06WhkiTMKQ7M4PepU-ZNv_DN0fkzJ3HY0Pj1oSOhe2EFcEtsoZc1Xmw7rRq-LfQ5HuWVgffw8t9-1sJfR7MoqqoeO2TZ4pNHg_C_1cSmmVzRD_HnKDOlV3PYW0P__EKmbe5aHi-jwgOn9Z8FJpPOJo87z9P4a-TAGdJ3MNNQzWMlS5X4F-QKbtnF7I),\"\nfeaturing Benjamin F. Cravatt, Ph.D., of Scripps Research, and Robert Abraham,\nPh.D., Chief Scientific Officer of Engine Biosciences. The discussion explored\nthe scientific rationale supporting next-generation PI3Kα pan-mutant\nselective inhibitors, including the importance of PI3Kα selectivity, the\npotential to overcome limitations of current therapies, and the Company's\nstructure-based drug design approach.\n\nOnKure also participated as an exhibitor and sponsor at the International\nSociety for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in\nPhiladelphia, held in May.\n\nFinancial Results\n\nCash position: As of June 30, 2026, the Company reported cash, cash\nequivalents, and marketable securities of $176.4 million, which is expected to\nprovide cash runway into 2029.\n\nResearch and development (R&D) expenses: R&D expenses were $12.6 million for\nboth the second quarter of 2026 and the second quarter of 2025. During the\nsecond quarter of 2026, an increase in clinical trial and outsourced\nmanufacturing expenses was offset by a decrease in outsourced preclinical R&D\nexpenses.\n\nGeneral and Administrative (G&A) expenses: G&A expenses were $4.3 million for\nthe second quarter of 2026, compared to $3.7 million for the second quarter of\n2025. The increase of $0.6 million was primarily driven by increases in\npersonnel-related and consulting costs.\n\nNet loss and net loss per share were $15.3 million, or $0.31 per share, for\nthe second quarter of 2026, compared to $15.4 million, or $1.14 per share, for\nthe second quarter of 2025.\n\nAbout OnKure Therapeutics\n\nOnKure Therapeutics (Nasdaq: OKUR) is a clinical-stage biopharmaceutical\ncompany focused on the discovery and development of best-in-class precision\nmedicines that target biologically validated drivers of vascular anomalies and\ncancers that are underserved by available therapies. Using a structure and\ncomputational chemistry-driven drug design platform, OnKure is committed to\nimproving clinical outcomes for patients by building a pipeline of small\nmolecule drugs designed to selectively target specific mutations thought to be\nkey drivers of vascular anomalies and cancer. OnKure aims to become a leader\nin targeting PI3Kα and has multiple programs designed to enable best-in-class\ntargeting of this important molecular target.\n\nFor more information about OnKure, visit us at www.onkure.com and follow us on\nLinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains forward-looking statements that involve\nsubstantial risks and uncertainties. All statements other than statements of\nhistorical facts contained in this press release are forward-looking\nstatements. Such forward-looking statements include, among other things,\nstatements regarding the potential of, and expectations regarding, OnKure’s\nproduct candidates and programs, including OKI-355 and OKI-345; OnKure’s\nability to discover, develop and advance additional programs; expected\nmilestones and the timing of such milestones, including the submission of IND\napplications for OKI-355 and OKI-345; OnKure’s expected cash runway; and\nstatements by OnKure’s President and Chief Executive Officer. In some cases,\nyou can identify forward-looking statements by terminology such as\n“believe,” “expect,” “estimate,” “intend,” “may,”\n“plan,” “potentially,” “will” or the negative of these terms or\nother similar expressions.\n\nThese forward-looking statements are based largely on OnKure’s current\nexpectations and projections about future events and trends that OnKure\nbelieves may affect its financial condition, results of operations, business\nstrategy and financial needs. These forward-looking statements are subject to\na number of risks, uncertainties and assumptions, including, among other\nthings: OnKure’s limited operating history; the significant net losses\nincurred since inception; the ability to raise additional capital to finance\noperations; the risk that actual uses of cash and cash equivalents differ from\nthe assumptions underlying OnKure’s expected cash runway; the ability to\nadvance product candidates through preclinical and clinical development; the\nability to obtain regulatory approval for, and ultimately commercialize,\nOnKure’s product candidates; the outcome of preclinical testing and early\nclinical trials for OnKure’s product candidates, including the ability of\nthose trials to satisfy relevant governmental or regulatory requirements and\nthe potential that the outcome of preclinical testing and early clinical\ntrials may not be predictive of the success of later clinical trials;\nOnKure’s limited resources; the risk of adverse events, toxicities or other\nundesirable side effects; potential delays or difficulties in the enrollment\nor maintenance of patients in clinical trials; the decision to develop or seek\nstrategic collaborations to develop OnKure’s current or future product\ncandidates in combination with other therapies and the cost of combination\ntherapies; OnKure’s limited experience in designing clinical trials and lack\nof experience in conducting clinical trials; the substantial competition\nOnKure faces in discovering, developing, or commercializing products;\nOnKure’s ability to protect its intellectual property and proprietary\ntechnologies; developments relating to OnKure’s competitors and its\nindustry, including competing product candidates and therapies; reliance on\nthird parties, contract manufacturers, and contract research organizations;\nlegislative, regulatory, political and economic developments and general\nmarket conditions; and those risks described in the section entitled “Risk\nFactors” in documents that OnKure files from time to time with the SEC,\nincluding its Annual Report on Form 10-K filed with the SEC on March 12, 2026,\nits Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 filed\nwith the SEC on August 4, 2026, and any subsequent filings with the SEC. These\nrisks are not exhaustive. New risk factors emerge from time to time, and it is\nnot possible for OnKure’s management to predict all risk factors, nor can\nOnKure assess the impact of all factors on OnKure’s business or the extent\nto which any factor, or combination of factors, may cause actual results to\ndiffer materially from those contained in, or implied by, any forward-looking\nstatements. You should not rely upon forward-looking statements as predictions\nof future events. Although OnKure believes that the expectations reflected in\nthe forward-looking statements are reasonable, OnKure cannot guarantee future\nresults, levels of activity, performance or achievements. Except as required\nby law, OnKure undertakes no obligation to update publicly any forward-looking\nstatements for any reason after the date of this press release.\n\nContact:\n\nDan Ferry\nLifeSci Advisors\ndaniel@lifesciadvisors.com\n\n\n\n ONKURE THERAPEUTICS, INC.                                                                                                         \n Condensed Consolidated Balance Sheets                                                                                             \n (In thousands, unaudited)                                                                                                         \n                                                                                                                                   \n                                                                           June 30, 2026                   December 31, 2025       \n                                                                                                                                   \n Assets                                                                                                                            \n Current assets:                                                                                                                   \n Cash, cash equivalents and marketable securities                          $        176,386                $          59,050       \n Prepaid expenses and other current assets                                          1,291                             1,789        \n Total current assets                                                               177,677                           60,839       \n Property and equipment, net                                                        435                               618          \n Operating lease, right-of-use asset                                                840                               387          \n Other assets                                                                       401                               273          \n Total assets                                                              $        179,353                $          62,117       \n Liabilities and Stockholders’ Equity                                                                                              \n Current liabilities:                                                                                                              \n Accounts payable, accrued expenses, and other current liabilities         $        6,307                  $          5,372        \n Operating lease liabilities, current portion                                       336                               549          \n Total current liabilities                                                          6,643                             5,921        \n Long-term liabilities                                                              602                               12           \n Total liabilities                                                                  7,245                             5,933        \n Stockholders’ equity                                                               172,108                           56,184       \n Total liabilities and stockholders’ equity                                $        179,353                $          62,117       \n\n\n\n ONKURE THERAPEUTICS, INC.                                                                                                                                               \n Condensed Consolidated Statements of Operations                                                                                                                         \n (In thousands, except share and per share data, unaudited)                                                                                                              \n                                                                                                                                                                         \n                                                          Three Months Ended                                          Six Months Ended                                   \n                                                          June 30,                                                    June 30,                                           \n                                                          2026                          2025                          2026                          2025                 \n Operating expenses:                                                                                                                                                     \n Research and development                                 $     12,611                  $     12,613                  $     24,318                  $     25,625         \n General and administrative                                     4,288                         3,711                         8,196                         7,699          \n Total operating expenses                                       16,899                        16,324                        32,514                        33,324         \n Loss from operations                                           (16,899     )                 (16,324     )                 (32,514     )                 (33,324     )  \n Other income:                                                                                                                                                           \n Interest income                                                1,553                         934                           2,011                         2,009          \n Total other income                                             1,553                         934                           2,011                         2,009          \n Net loss                                                 $     (15,346     )           $     (15,390     )           $     (30,503     )           $     (31,315     )  \n                                                                                                                                                                         \n Net loss per share attributable to common stockholders:                                                                                                                 \n Basic and diluted                                        $     (0.31       )           $     (1.14       )           $     (0.96       )           $     (2.33       )  \n Weighted average shares outstanding:                                                                                                                                    \n Basic and diluted                                              49,869,177                    13,509,080                    31,871,862                    13,466,942     \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b01f7b95-9b60-4b2b-8515-fe0cae183fff)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-04T20:05:03.412026446Z","server_sent_at_ms":1785873903412},"received_at":"2026-08-04T20:05:03.490Z","source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338800/0/en/onkure-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-highlights.html"},"analysis":{"id":"97582","press_release_id":"108568","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"OnKure reported $176.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which it expects will fund operations into 2029.\n\nThe company continues IND-enabling activities for its lead candidates, OKI-345 for breast cancer and OKI-355 for vascular anomalies, with IND submissions planned for the first half of 2027.\n\nFor the second quarter, R&D expenses were $12.6 million and G&A expenses were $4.3 million, resulting in a net loss of $15.3 million, or $0.31 per share.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Strong cash runway into 2029 supports continued advancement of PI3Kα pipeline."},"keyFigures":{"revenue":0,"revenueYoy":0,"customDimensions":{"net_loss":"$15.3 million","cash_runway":"$176.4 million","ga_expenses":"$4.3 million","rd_expenses":"$12.6 million"}},"quotedText":"We believe the combination of our chemistry platform and deep understanding of PI3Kα biology positions us to develop differentiated therapies with the potential to meaningfully improve outcomes for patients.","namedEntities":{"people":[{"name":"Nicholas Saccomano","role":"President and Chief Executive Officer"},{"name":"Benjamin F. Cravatt","role":"Scripps Research"},{"name":"Robert Abraham","role":"Chief Scientific Officer of Engine Biosciences"}],"products":["OKI-345","OKI-355"],"companies":[{"name":"OnKure Therapeutics, Inc.","ticker":"OKUR"},{"name":"Engine Biosciences","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$176.4 million","context":"cash, cash equivalents, and marketable securities as of June 30, 2026"},{"amount":"$12.6 million","context":"R&D expenses for Q2 2026"},{"amount":"$4.3 million","context":"G&A expenses for Q2 2026"},{"amount":"$15.3 million","context":"net loss for Q2 2026"},{"amount":"$0.31 per share","context":"net loss per share for Q2 2026"}]},"materialImpact":{"score":3,"reasoning":"Routine quarterly results with a strong cash position update ($176M runway into 2029) and progress on IND-enabling activities for lead drug candidates. While the cash position is significant for a clinical-stage biotech, the results are largely operational progress and financial stewardship rather than a binary clinical or regulatory event."},"tickerRelevance":{"others":[],"primary":"OKUR"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":["earnings"],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"routine-operational-update","sectorWeight":"biotech","cashPositionSignificance":"high"}},"event_type":"operations_update","event_type_secondary":["earnings"],"sentiment":"bullish","material_impact_score":3,"narrative":"OnKure reported $176.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which it expects will fund operations into 2029.\n\nThe company continues IND-enabling activities for its lead candidates, OKI-345 for breast cancer and OKI-355 for vascular anomalies, with IND submissions planned for the first half of 2027.\n\nFor the second quarter, R&D expenses were $12.6 million and G&A expenses were $4.3 million, resulting in a net loss of $15.3 million, or $0.31 per share.","key_figures":{"revenue":0,"revenueYoy":0,"customDimensions":{"net_loss":"$15.3 million","cash_runway":"$176.4 million","ga_expenses":"$4.3 million","rd_expenses":"$12.6 million"}},"named_entities":{"people":[{"name":"Nicholas Saccomano","role":"President and Chief Executive Officer"},{"name":"Benjamin F. Cravatt","role":"Scripps Research"},{"name":"Robert Abraham","role":"Chief Scientific Officer of Engine Biosciences"}],"products":["OKI-345","OKI-355"],"companies":[{"name":"OnKure Therapeutics, Inc.","ticker":"OKUR"},{"name":"Engine Biosciences","relationship":"mentioned"}],"dollarAmounts":[{"amount":"$176.4 million","context":"cash, cash equivalents, and marketable securities as of June 30, 2026"},{"amount":"$12.6 million","context":"R&D expenses for Q2 2026"},{"amount":"$4.3 million","context":"G&A expenses for Q2 2026"},{"amount":"$15.3 million","context":"net loss for Q2 2026"},{"amount":"$0.31 per share","context":"net loss per share for Q2 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T02:20:57.709Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"routine-operational-update","sectorWeight":"biotech","cashPositionSignificance":"high"}},"durationMs":247178,"modelName":"glm-4.7"}}